SKP2 and prostate carcinoma: As a result of SKP2 overexpression, LNCaP-SKP2 cells exhibited downregulation of the cyclin-dependent kinase inhibitor p27, a hallmark of aggressive prostate cancer (Supplementary Figure 7).